GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jeil Pharma Holdings Inc (XKRX:002620) » Definitions » Price-to-Owner-Earnings

Jeil Pharma Holdings (XKRX:002620) Price-to-Owner-Earnings : (As of May. 25, 2024)


View and export this data going back to 1988. Start your Free Trial

What is Jeil Pharma Holdings Price-to-Owner-Earnings?

As of today (2024-05-25), Jeil Pharma Holdings's share price is ₩10400.00. Jeil Pharma Holdings does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Jeil Pharma Holdings's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Jeil Pharma Holdings was 162.65. The lowest was 0.18. And the median was 13.05.


XKRX:002620's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 27.13
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-25), Jeil Pharma Holdings's share price is ₩10400.00. Jeil Pharma Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-1,695.00. Therefore, Jeil Pharma Holdings's PE Ratio for today is At Loss.

As of today (2024-05-25), Jeil Pharma Holdings's share price is ₩10400.00. Jeil Pharma Holdings's EPS without NRI for the trailing twelve months (TTM) ended in was ₩-1,609.19. Therefore, Jeil Pharma Holdings's PE Ratio without NRI for today is At Loss.

During the past 13 years, Jeil Pharma Holdings's highest PE Ratio without NRI was 253.09. The lowest was 0.00. And the median was 52.68.


Jeil Pharma Holdings Price-to-Owner-Earnings Historical Data

The historical data trend for Jeil Pharma Holdings's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jeil Pharma Holdings Price-to-Owner-Earnings Chart

Jeil Pharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 12.50 - -

Jeil Pharma Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Jeil Pharma Holdings's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Jeil Pharma Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jeil Pharma Holdings's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jeil Pharma Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Jeil Pharma Holdings's Price-to-Owner-Earnings falls into.



Jeil Pharma Holdings Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Jeil Pharma Holdings's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=10400.00/-1470.81
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jeil Pharma Holdings  (XKRX:002620) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Jeil Pharma Holdings Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Jeil Pharma Holdings's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Jeil Pharma Holdings (XKRX:002620) Business Description

Traded in Other Exchanges
N/A
Address
745-5, Banpo-dong, Seocho-gu, Seoul, KOR, 137-810
Jeil Pharma Holdings Inc is involved in manufacture and distribution of pharmaceutical products. The company mainly produces finished pharmaceutical products and active pharmaceutical ingredients. It has categorized its products in Antibiotic, Oncology, Cardiovascular, Gastrointestinal, Urology, Respiratory etc. The firm's manufacturing facility and research and development institute located at Yongin-si, Gyeonggi-do in Korea.

Jeil Pharma Holdings (XKRX:002620) Headlines

No Headlines